Broadcom named strategic vendor for Walmart virtualization solutions
Introduction & Market Context
Tandem Diabetes Care (NASDAQ:TNDM) presented its company overview on April 30, 2025, highlighting its strategic positioning in the diabetes care market with a focus on automated insulin delivery (AID) systems. The company serves a significantly underpenetrated market, with less than 40% of approximately 2 million people with type 1 diabetes in the U.S. using insulin pumps, and even lower penetration rates internationally and among type 2 diabetes patients.
Despite reporting strong Q4 2024 results with an EPS of $0.01 (beating forecasts of -$0.21) and revenue of $282.65 million (exceeding expectations by over $31 million), Tandem’s stock fell 17.26% in after-hours trading, reflecting investor concerns about future profitability despite the company’s growth trajectory.
As shown in the following slide, Tandem has established a significant presence with approximately 480,000 in-warranty customers across 25 countries:
Product Portfolio and Technology
Tandem’s strategy centers on offering patients choice through its dual-platform approach, featuring the t:slim X2 insulin pump and the newer Tandem Mobi system. Both platforms are powered by the company’s Control-IQ+ Technology, which is FDA-cleared for type 1 diabetes (ages 2+) and type 2 diabetes (ages 18+).
The company’s product portfolio is clearly illustrated in this comprehensive overview:
The Tandem Mobi system, described as the "World’s smallest, durable automated insulin delivery system," is 55% smaller than other insulin pumps and has achieved 95% satisfaction among early access participants. This compact device offers flexible wearing options and mobile control capabilities.
A key competitive advantage for Tandem is its integration with multiple continuous glucose monitoring (CGM) systems, providing patients with more options than competing platforms. The t:slim X2 is the first insulin pump in the United States to integrate with three different CGM sensors.
As shown in the following slide, Tandem’s systems work with both Dexcom (NASDAQ:DXCM) and Abbott CGM products:
Financial Performance and Outlook
Tandem reported robust financial results for 2024, with worldwide sales reaching $910 million, representing an 18% increase year-over-year. Q4 2024 sales hit a record $252 million, marking a 20% rise from the previous year, driven by a 13% increase in U.S. sales and a 39% surge in international markets.
The company’s sales growth trajectory is illustrated in this chart:
For 2025, Tandem projects worldwide sales between $997 million and $1 billion, representing 10-11% growth. U.S. sales are expected to increase by 13-14%, with modest contributions from the pharmacy channel.
The company’s financial targets include improving its gross margin from 51% in 2024 to 54% in 2025, and adjusted EBITDA margin from -1% to 3%. Long-term, Tandem aims to achieve 65% gross margin and 25% operating margin through various efficiency initiatives and scale advantages.
Growth Strategy and Pipeline
Tandem’s growth strategy focuses on several key drivers, including scaling the launch of Tandem Mobi (with Android and international availability beginning in 2025), worldwide integration with Abbott Freestyle Libre 3 Plus, an expanded U.S. sales force, preparation for direct sales in select European countries in 2026, and increasing pharmacy channel access.
The company sees significant opportunity in the type 2 diabetes market, with CEO John Sheridan stating an ambition to capture over 25% of this market within the next three and a half years. Currently, only about 5% of the more than 2 million people with type 2 insulin-intensive diabetes in the U.S. use an insulin pump.
Tandem’s robust product pipeline is detailed in this slide:
The company is also developing the Tandem Source platform as a comprehensive diabetes management solution for patients, caregivers, and healthcare providers. This platform is currently available in the U.S. and Canada, with additional countries launching in 2025.
Investor Reaction and Challenges
Despite Tandem’s positive earnings surprise and strong sales growth, the market reaction has been cautious. The stock fell 17.26% in after-hours trading following the earnings announcement, with shares dropping to $27.79. According to the earnings report, nine analysts have recently revised their earnings estimates downward for upcoming periods, signaling concerns about future profitability.
The company faces several challenges, including competitive pressures in the AID market, ongoing negative EPS forecasts that may affect investor confidence, and potential difficulties in achieving projected improvements in gross and EBITDA margins. Additionally, macroeconomic factors and exchange rate fluctuations could impact international sales.
Tandem’s comprehensive strategy for addressing these challenges and delivering on its financial targets is outlined in this slide:
While Tandem’s presentation paints an optimistic picture of its growth prospects and market position, investors appear to be taking a more cautious view, weighing the company’s strong recent performance against concerns about long-term profitability in an increasingly competitive market.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.